Fig. 2From: Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016Kaplan-Meier 28 day survival estimates among ESBL-producing E. coli BSI patients depending on treatment with carbapenem or β-lactam-β-lactamase inhibitor (BLBLI) combination antibioticsBack to article page